Today, we’re diving into the breakup between Salesforce and Veeva as it reshapes the Life Sciences industry.
Across Pharma and MedTech, the deadline is approaching far too quickly to stay with Veeva or move to Salesforce Life Sciences Cloud. This is a long-term strategic decision, one that will shape how companies operate, compete, and innovate for years to come. And now that decision has been expedited and for the transition to be completed by December 2029.
Why This Decision Is Happening Now
The simplest way to understand this decision moment is that it feels like a divorce of platforms with the child being the pharma or medtech company. For over 15 years, companies had the best of both worlds. Veeva delivered a best-in-class commercial CRM application for Life Sciences, and it was built on the flexibility and scalability of the Salesforce platform. This seemed to be a successful marriage leaning on the best strengths of both partners. And this is where I say all good things must come to an end.
Veeva is moving off the Salesforce platform and transitioning its applications to its own proprietary ecosystem called Veeva Vault. In fact, the agreement between Veeva and Salesforce has already come to an end.
At the same time, Salesforce, known for its targeted industry applications, doubled down on launching Life Sciences Cloud nearly 2 years ago. The Life Sciences Cloud application is natively built on the Salesforce platform.
As a result, what many companies are using today is effectively becoming a legacy path. Organizations are being forced to migrate to Veeva Systems or stay with Salesforce and implement their most recent application, Life Sciences Cloud.
How are Veeva & Salesforce different?
The most important question, the one that changes everything about this decision, is about the platform philosophy, not features.
Veeva is a best in class application for life sciences. It’s deep, it’s powerful, and it’s built specifically for commercial pharma reps for speed, sample management, and compliance.
Salesforce Life Sciences Cloud is a unified platform, purpose-built for Life Sciences and natively connected across the Salesforce ecosystem.
So the real difference here is that Salesforce is a platform play. It natively talks to the other areas of a life sciences organization, unifying their data across sales, field service, support, marketing journeys, and more to draw valuable insights that can be turned into action. This is all done in a compliant, patient-centric approach.
To summarize this plainly, the real choice is a silo’d versus platform play and that distinction matters more than any individual feature.
What Should Companies Actually Evaluate?
Many organizations fall into the trap of running a feature-by-feature bake-off. That approach misses the point. This decision should be grounded in two fundamental questions:
1. What is your business model?
If your business is primarily:
- Selling to healthcare providers
- Driven by sales rep efficiency
- Focused on commercial execution
Then a specialized solution like Veeva may be highly effective.
But if your business involves:
- Patient engagement
- Longitudinal care journeys
- Cross-functional collaboration
Then a unified platform becomes significantly more valuable.
2. What data will drive your competitive advantage?
This is where the decision becomes clearer. If the organization’s most valuable data lives within sales operations, a siloed, industry leading system like Veeva can work.
But if your future depends on:
- Connecting patient, provider, and product data
- Integrating across departments
- Leveraging data for outcomes-based models
Then you need a platform that can ingest, unify, and activate data across the enterprise.
Ultimately, this is a question of whether you see data as a supporting asset or your primary competitive advantage.
What Option is the Right Fit?
Every organization is different, but from what we see across our Life Sciences implementations, clear patterns emerge.
Stay with Veeva if:
- You are a large, traditional pharma company
- ~90% of your model is HCP sales
- Your priority is a deeply specialized, out-of-the-box CRM
- You value stability and a proven commercial model
In this scenario, Veeva is a safe and effective choice.
Choose Salesforce Life Sciences Cloud if:
- You are a MedTech company managing both B2B sales and patient relationships
- You are in specialty pharma, where adherence and patient support are core to your offering
- You are moving toward value-based care models
- You already use Salesforce across other parts of your enterprise
In these cases, the ability to connect data, teams, and experiences on a single platform becomes a major advantage.
There’s also a practical consideration:
If your teams are already using Veeva on Salesforce today, they’re already familiar with the Salesforce interface. This means the change management friction is reduced by staying with Salesforce. That’s a short term consideration but nonetheless, something to think about.
How Ateko Helps You Get This Right
At Ateko, we take the approach of understanding your business first and defining the IT project second. If you simply decide to move to Life Sciences Cloud, the biggest mistake you can make is to spend millions of dollars over two years, just to rebuild your old, clunky process in a new shiny platform.
We begin by asking things like:
- What is the one win you need right now?
- Do you require faster patient onboarding?
- Better adherence?
- More effective field engagement?
Then we build in phases, building what’s most important to your business first. We build in a way that the users of the platform can really feel those early wins.
We’re not just a Salesforce implementation partner, we’re value partners. That means we challenge assumptions, push beyond lift-and-shift thinking, and ensure that if you are to choose Salesforce we deliver measurable business impact.
If you’re ready to make that call, we’d love to talk.
